V-AKT murine thymoma viral oncogene homolog/mammalian target of rapamycin activation induces a module of metabolic changes contributing to growth in insulin-induced hepatocarcinogenesis

Hepatology

Volumn 55, Issue 5, 2012, Pages 1473-1484

  Evert, Matthias ^a   Calvisi, Diego F ^a   Evert, Katja ^a   De Murtas, Valentina ^a   Gasparetti, Gioia ^a   Mattu, Sandra ^a   Destefanis, Giulia ^a   Ladu, Sara ^b   Zimmermann, Antje ^a   Delogu, Salvatore ^a   Thiel, Sara ^a   Thiele, Andrea ^a   Ribback, Silvia ^a   Dombrowski, Frank ^a  

^a UNIVERSITY OF GREIFSWALD   (Germany)

^b UNIVERSITY OF CHIETI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; ACYL COENZYME A DESATURASE; FATTY ACID SYNTHASE; GLUCOSE 6 PHOSPHATE DEHYDROGENASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INITIATION FACTOR 4E; INSULIN; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PENTOSE PHOSPHATE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN S6; RHEB PROTEIN; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER GROWTH; CELL METABOLISM; CELL PROLIFERATION; CHOLESTEROL SYNTHESIS; CONTROLLED STUDY; ENZYME ACTIVATION; FATTY ACID OXIDATION; FATTY ACID SYNTHESIS; GLUCONEOGENESIS; GLYCOLYSIS; HUMAN; HUMAN CELL; HYPERINSULINISM; IN VITRO STUDY; IN VIVO STUDY; LIPOGENESIS; LIVER CARCINOGENESIS; LIVER CELL; LIVER CELL CARCINOMA; MALE; NONHUMAN; PANCREAS ISLET TRANSPLANTATION; PENTOSE PHOSPHATE CYCLE; PRIORITY JOURNAL; RAT;

ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; DIABETES MELLITUS, EXPERIMENTAL; DISEASE MODELS, ANIMAL; FATTY ACIDS; HYPERINSULINISM; IMMUNOBLOTTING; LIPOGENESIS; LIVER NEOPLASMS; MALE; MICE; PROTO-ONCOGENE PROTEINS C-AKT; RANDOM ALLOCATION; RATS; RATS, INBRED LEW; SENSITIVITY AND SPECIFICITY; SIROLIMUS; STREPTOZOCIN; THYMOMA; TOR SERINE-THREONINE KINASES; TRANSFECTION;

EID: 84859978328     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.25600     Document Type: Article

References (42)

1. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007; 132: 2557-2576.
2. Adams LA, Lymp JF, St Sauver J, Sanderson SO, Lindor KD, Feldstein A. The natural history of nonalcoholic fatty liver disease: a population based cohort study. Gastroenterology 2005; 129: 113-121.
3. Siegel AB, Zhu AX. Metabolic syndrome and hepatocellular carcinoma: two growing epidemics with a potential link. Cancer 2009; 115: 5651-5661.
4. Starley BQ, Calcagno CJ, Harrison SA. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. HEPATOLOGY 2010; 51: 1820-1832.
5. Welzel TM, Graubard BI, Zeuzem S, El-Serag HB, Davila JA, McGlynn KA. Metabolic syndrome increases the risk of primary liver cancer in the United States: a study in the SEER-Medicare database. HEPATOLOGY 2011; 54: 463-471.
6. Cotrim HP, Parana R, Braga E, Lyra L. Nonalcoholic steatohepatitis and hepatocellular carcinoma: natural history? Am J Gastroenterol 2000; 5: 3018-3019.
7. Zen Y, Katayanagi K, Tsuneyama K, Harada K, Araki I, Nakanuma Y. Hepatocellular carcinoma arising in non-alcoholic steatohepatitis. Pathol Int 2011; 51: 127-131.
8. Adinolfi LE, Gambardella M, Andreana A, Tripodi MF, Utili R, Ruggiero G. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. HEPATOLOGY 2001; 33: 1358-1364.
9. Westin J, Nordlinder H, Lagging M, Norkrans G, Wejstal R. Steatosis accelerates fibrosis development over time in hepatitis C virus genotype 3 infected patients. J Hepatol 2002; 37: 837-842.
10. Adami HO, Chow WH, Nyren O, Berne C, Linet MS, Ekbom A, et al. Excess risk of primary liver cancer in patients with diabetes mellitus. J Natl Cancer Inst 1996; 88: 1472-1477.
11. El-Serag HB, Hampel H, Javadi F. The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence. Clin Gastroenterol Hepatol 2006; 4: 369-380.
12. Wideroff L, Gridley G, Mellemkjaer L, Chow WH, Linet M, Keehn S, et al. Cancer incidence in a population-based cohort of patients hospitalized with diabetes mellitus in Denmark. J Natl Cancer Inst 1997; 89: 1360-1365.
13. Lee MS, Hsu CC, Wahlqvist ML, Tsai HN, Chang YH, Huang YC. Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in Taiwanese: a representative population prospective cohort study of 800, 000 individuals. BMC Cancer 2011; 11: 20.
14. Dawson LK, Hamilton LA. Risk of cancer in patients receiving insulin glargine. Am J Health Syst Pharm 2010; 67: 2025-2031.
15. Werner H, Weinstein D, Yehezkel E, Laron Z. Controversies in the use of insulin analogues. Expert Opin Biol Ther 2011; 11: 199-209.
16. Bucher ML, Swaffield MN. Regulation of hepatic regeneration in rats by synergistic action of insulin and glucagon. Proc Natl Acad Sci U S A 1975; 72: 1157-1160.
17. Reed GB, Grisham JW. Insulin and hydrocortisone effects on viability and glycogen stores of postnatal rat liver organ culture. Lab Invest 1975; 33: 298-304.
18. Starzl TE, Watanabe K, Porter KA, Putnam CW. Effects of insulin, glucagon, and insuling/glucagon infusions on liver morphology and cell division after complete portacaval shunt in dogs. Lancet 1976; 1: 821-825.
19. Dombrowski F, Lehringer-Polzin M, Pfeifer U. Hyperproliferative liver acini after intraportal islet transplantation in streptozotocin-induced diabetic rats. Lab. Invest 1994; 71: 688-699.
20. Dombrowski F, Filsinger E, Bannasch P, Pfeifer U. Altered liver acini induced in diabetic rats by portal vein islet isografts resemble preneoplastic hepatic foci in their enzymic pattern. Am J Pathol 1996; 148: 1249-1256.
21. Dombrowski F, Bannasch P, Pfeifer U. Hepatocellular neoplasms induced by low-number pancreatic islet transplants in streptozotocin diabetic rats. Am J Pathol 1997; 150: 1071-1087.
22. Dombrowski F, Mathieu C, Evert M. Hepatocellular neoplasms induced by low-number pancreatic islet transplants in autoimmune diabetic BB/Pfd rats. Cancer Res 2006; 66: 1833-1843.
23. Evert M, Sun J, Pichler S, Slavova N, Schneider-Stock R, Dombrowski F. Insulin receptor, insulin receptor substrate-1, Raf-1, and Mek-1 during hormonal hepatocarcinogenesis by intrahepatic pancreatic islet transplantation in diabetic rats. Cancer Res 2004; 64: 8093-8100.
24. Bannasch P, Zerban H. Pathology of tumours in laboratory animals. Tumours of the rat. Tumours of the liver. IARC Sci Publ 1990; 99: 199-240.
25. Zhang HH, Huang J, Düvel K, Boback B, Wu S, Squillace RM, et al. Insulin stimulates adipogenesis through the Akt-TSC2-mTORC1 pathway. PloS One 2009; 4: e6189.
26. Calvisi DF, Wang C, Ho C, Ladu S, Lee SA, Mattu S, et al. Increased lipogenesis, induced by AKT-mTORC1-RPS6 signaling, promotes development of human hepatocellular carcinoma. Gastroenterology 2011; 140: 1071-1083.
27. Luo Z, Zang M, Guo W. AMPK as a metabolic tumor suppressor: control of metabolism and cell growth. Future Oncol 2010; 6: 457-470.
28. Ma J, Yan R, Zu X, Cheng JM, Rao K, Liao DF, et al. AKR1B10 affects fatty acid synthesis by regulating the stability of acetyl-CoA carboxylase-alpha in breast cancer cells. J Biol Chem 2008; 283: 3418-3423.
29. Yecies JL, Zhang HH, Menon S, Liu S, Yecies D, Lipovsky AI, et al. Akt stimulates hepatic SREBP1c and lipogenesis through parallel mTORC1-dependent and independent pathways. Cell Metab 2011; 14: 21-32.
30. Robey RB, Hay N. Is Akt the "Warburg kinase"?-Akt-energy metabolism interactions and oncogenesis. Semin Cancer Biol 2009; 19: 25-31.
31. Wu Z, Jiao P, Huang X, Feng B, Feng Y, Yang S, et al. MAPK phosphatase-3 promotes hepatic gluconeogenesis through dephosphorylation of forkhead box O1 in mice. J Clin Invest 2010; 120: 3901-3911.
32. Hay N. The Akt-mTOR tango and its relevance to cancer. Cancer Cell 2005; 8: 179-183.
33. Stambolic V, Suzuki A, de la Pompa JL, Brothers GM, Mirtsos C, Sasaki T, et al. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 1998; 95: 29-39.
34. Du K, Herzig S, Kulkarni RN, Montminy M. TRB3: a tribbles homolog that inhibits Akt/PKB activation by insulin in liver. Science 2003; 300, 1574-1577.
35. Qi L, Heredia JE, Altarejos JY, Screaton R, Goebel N, Niessen S, et al. TRB3 links the E3 ubiquitin ligase COP1 to lipid metabolism. Science 2006; 312: 1763-1766.
36. Brognard J, Newton AC. PHLiPPing the switch on Akt and protein kinase C signaling. Trends Endocrinol Metab 2008; 19: 223-230.
37. Laplante M, Sabatini DM. mTORC1 activates SREBP-1c and uncouples lipogenesis from gluconeogenesis. Proc Natl Acad Sci U S A 2010; 107: 3281-3282.
38. Li S, Brown MS, Goldstein JL. Bifurcation of insulin signaling pathway in rat liver: mTORC1 required for stimulation of lipogenesis, but not inhibition of gluconeogenesis. Proc Natl Acad Sci U S A 2010; 107: 3441-3446.
39. Masuda M, Shimomura M, Kobayashi K, Kojima S, Nakatsura T. Growth inhibition by NVP-BEZ235, a dual PI3K/mTOR inhibitor, in hepatocellular carcinoma cell lines. Oncol Rep 2011; 26: 1273-1279.
40. Donadon V, Balbi M, Ghersetti M, Grazioli S, Perciaccante A, Della Valentina G, et al. Antidiabetic therapy and increased risk of hepatocellular carcinoma in chronic liver disease. World J Gastroenterol 2009; 15: 2506-2511.
41. Chen TM, Lin CC, Huang PT, Wen CF. Metformin associated with lower mortality in diabetic patients with early stage hepatocellular carcinoma after radiofrequency ablation. J Gastroenterol Hepatol 2011; 26: 858-865.
42. Nkontchou G, Cosson E, Aout M, Mahmoudi A, Bourcier V, Charif I, et al. Impact of metformin on the prognosis of cirrhosis induced by viral hepatitis C in diabetic patients. J Clin Endocrinol Metab 2011; 96: 2601-2608.